Podcast appearances and mentions of Harry P Erba

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Upon completion of this activity, participants should be better able to: Recognize prognostic patient- and disease-related features, including age, cytogenetics, and mutational status, that are relevant for treatment decisions in AML, Discuss updated efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Manage the unique spectrum of treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/VKE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in the management of acute myeloid leukemia (AML), including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. The expert also focuses on the relevance of such evidence for the management of diverse AML populations, including patients with high-risk or mutation-defined disease, or those who are fit or unfit for intensive therapy. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/VKE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in the management of acute myeloid leukemia (AML), including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. The expert also focuses on the relevance of such evidence for the management of diverse AML populations, including patients with high-risk or mutation-defined disease, or those who are fit or unfit for intensive therapy. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/VKE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in the management of acute myeloid leukemia (AML), including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. The expert also focuses on the relevance of such evidence for the management of diverse AML populations, including patients with high-risk or mutation-defined disease, or those who are fit or unfit for intensive therapy. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/VKE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in the management of acute myeloid leukemia (AML), including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. The expert also focuses on the relevance of such evidence for the management of diverse AML populations, including patients with high-risk or mutation-defined disease, or those who are fit or unfit for intensive therapy. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/VKE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in the management of acute myeloid leukemia (AML), including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. The expert also focuses on the relevance of such evidence for the management of diverse AML populations, including patients with high-risk or mutation-defined disease, or those who are fit or unfit for intensive therapy. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/VKE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in the management of acute myeloid leukemia (AML), including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. The expert also focuses on the relevance of such evidence for the management of diverse AML populations, including patients with high-risk or mutation-defined disease, or those who are fit or unfit for intensive therapy. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/VKE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in the management of acute myeloid leukemia (AML), including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. The expert also focuses on the relevance of such evidence for the management of diverse AML populations, including patients with high-risk or mutation-defined disease, or those who are fit or unfit for intensive therapy. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/VKE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in the management of acute myeloid leukemia (AML), including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. The expert also focuses on the relevance of such evidence for the management of diverse AML populations, including patients with high-risk or mutation-defined disease, or those who are fit or unfit for intensive therapy. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.